China
Africa
Explore chapters and articles related to this topic
Nucleic Acids as Therapeutic Targets and Agents
Published in David E. Thurston, Ilona Pysz, Chemistry and Pharmacology of Anticancer Drugs, 2021
Pixantrone was shown to have promising clinical activity in a number of clinical trials in heavily pretreated non-Hodgkin’s lymphoma patients, and to have potentially reduced cardiotoxicity compared to mitoxantrone. On this basis, the FDA initially granted fast track designation for the treatment of patients with relapsed or refractory aggressive NHL. However, the primary efficacy endpoint did not reach significance, and in 2010 the FDA did not approve the agent, instead asking for further clinical studies to be conducted. Although still not approved by the FDA at the time of writing, in 2009 pixantrone became available in Europe on a named patient basis. Furthermore, it received conditional approval by the European Commission (EC) in 2012, and in 2019 Servier announced that the EC had approved conversion of the conditional approval into a standard marketing authorization as a single agent for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin’s B-cell lymphoma.
P
Published in Caroline Ashley, Aileen Dunleavy, John Cunningham, The Renal Drug Handbook, 2018
Caroline Ashley, Aileen Dunleavy, John Cunningham
Pixantrone may be metabolised in the liver and/or excreted in the bile. As metabolism appears to be limited, biliary excretion of unchanged pixantrone may be the major elimination pathway. Acetylated metabolites were pharmacologically inactive and metabolically stable.
Pixantrone: novel mode of action and clinical readouts
Published in Expert Review of Hematology, 2018
Giorgio Minotti, Haiyong Han, Valérie Cattan, Anton Egorov, Francesco Bertoni
Pixantrone, an aza-anthracenedione, is one of the treatment options for heavily pretreated NHL patients. It is the first monotherapy approved by the European Medicines Agency as third- or fourth-line treatment for aggressive B-cell NHL [6,7]. The evidence for its efficacy in heavily pretreated patients is acknowledged in current European Society of Medical Oncology guidelines [3], and it is recommended as a third- or fourth-line treatment option in the UK [8]. While pixantrone is commonly perceived to be an anthracycline-like drug, it has a unique chemical structure and distinct pharmacologic properties. This narrative review explores the mode of action of pixantrone, contrasting it with that of the anthracycline doxorubicin and the anthracenedione mitoxantrone, and also provides a brief overview of pixantrone’s efficacy and safety profiles.
An evaluation of pixantrone for the treatment of non-Hodgkin’s lymphoma
Published in Expert Opinion on Pharmacotherapy, 2018
It is unlikely that pixantrone will play a role as part of first-line therapy in aggressive lymphomas (except for patients with preexisting impairment of cardiac function). Even if PIX306 failed the primary end point, pixantrone it will be an important treatment option in the relapse setting. Additional studies are needed to evaluate the role of pixantrone in combination with other compounds, especially with upcoming targeted therapies, and to confirm the effectiveness of pixantrone in other lymphoma subtypes, e.g. follicular lymphomas.